Thelansis

 Urothelial Carcinoma (UC), also called Transitional cell carcinoma (TCC), includes cancer in the renal pelvis, ureters, and bladder. The clinical spectrum of TCC in the urinary system can be divided into noninvasive/superficial tumors, invasive, and metastatic lesions. HE4 biomarkers are elevated in the serum of patients diagnosed with TCC in the urinary system regardless of the TNM stage. Urothelial carcinoma (or UCC) accounts for about 90% of all bladder cancers. UC of the urinary bladder confers significant mortality, and patients often require an aggressive therapeutic strategy. Although advanced and metastatic urothelial carcinoma (mUC) of the bladder is a small subset of all urothelial tumors, it accounts for the majority of the disease's rapid mortality. Prior to combination cisplatin-based chemotherapy, median survival in the mUC setting was only 4 to 6 months. While an improvement, relapse and progression are still very common in this disease, and second-line chemotherapi